<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2558121-A4" country="EP" doc-number="2558121" kind="A4" date="20140108" family-id="44709938" file-reference-id="262422" date-produced="20180825" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146616115" ucid="EP-2558121-A4"><document-id><country>EP</country><doc-number>2558121</doc-number><kind>A4</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-11763537-A" is-representative="NO"><document-id mxw-id="PAPP154890442" load-source="docdb" format="epo"><country>EP</country><doc-number>11763537</doc-number><kind>A</kind><date>20110401</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220404534" load-source="docdb" format="original"><country>EP</country><doc-number>11763537.5</doc-number><date>20110401</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140549544" ucid="US-2011030998-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2011030998</doc-number><kind>W</kind><date>20110401</date></document-id></priority-claim><priority-claim mxw-id="PPC140549084" ucid="US-32023010-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>32023010</doc-number><kind>P</kind><date>20100401</date></document-id></priority-claim></priority-claims><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989637777" load-source="docdb">A61P  39/00        20060101ALI20131129BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989641682" load-source="docdb">C07K  16/28        20060101AFI20131129BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989647337" load-source="docdb">A61K  39/395       20060101ALI20131129BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989620659" load-source="docdb" scheme="CPC">G01N  33/57426     20130101 FI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989625644" load-source="docdb" scheme="CPC">C07K2317/732       20130101 LA20130125BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989626064" load-source="docdb" scheme="CPC">G01N  33/57407     20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989629411" load-source="docdb" scheme="CPC">G01N2800/52        20130101 LA20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989634647" load-source="docdb" scheme="CPC">C07K2317/41        20130101 LA20130125BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989640855" load-source="docdb" scheme="CPC">C07K  16/2866      20130101 LI20130125BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989644541" load-source="docdb" scheme="CPC">G01N2333/715       20130101 LA20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132405597" lang="DE" load-source="docdb">EPHA3-ANTIKÖRPER ZUR BEHANDLUNG MULTIPLER MYELOME</invention-title><invention-title mxw-id="PT132405598" lang="EN" load-source="docdb">EPHA3 ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA</invention-title><invention-title mxw-id="PT132405599" lang="FR" load-source="docdb">ANTICORPS ANTI-EPHA3 POUR LE TRAITEMENT DU MYÉLOME MULTIPLE</invention-title><citations><non-patent-citations><nplcit><text>ANONYMOUS: "KaloBios Initiates Phase 1 Clinical Trial of KB004 in EphA3-Expressing Hematologic Malignancies", 23 March 2013 (2013-03-23), pages 1 - 2, XP002716990, Retrieved from the Internet &lt;URL:http://www.bloomberg.com/apps/news?pid=21070001&amp;sid=aqNLkL0O94uk&gt; [retrieved on 20131126]</text><sources><source mxw-id="PNPL67387027" load-source="docdb" name="SEA" category="T"/></sources></nplcit><nplcit><text>ARRUGA FRANCESCA ET AL: "EphA3 is abnormally expressed in chronic myeloprolipherative disorders and could represent a new molecular target", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 50, 1 April 2009 (2009-04-01), pages 692, XP009137278, ISSN: 0197-016X</text><sources><source mxw-id="PNPL67387028" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>CILLONI DANIELA ET AL: "EphA3 Kinase Is Constitutively Activated in Chronic Myeloid Leukaemia during Progression to Accelerated and Blast Crisis and It Could Represent a New Molecular Target", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 112, no. 11, 1 November 2008 (2008-11-01), pages 399, XP009137279, ISSN: 0006-4971</text><sources><source mxw-id="PNPL67387029" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>CILLONI ET AL.: "EPHA3 IS ABNORMALLY EXPRESSED IN CHRONIC MYELOPROLIPHERATIVE DISORDERS AND CAN BE TARGETED BY DASATINIB OR BY MONOCLONAL ANTIBODIES", HEMATOLOGICA, June 2007 (2007-06-01), pages 1 - 1, XP002716994, Retrieved from the Internet &lt;URL:http://online.haematologica.org/eha12/browserecord_prt.php?-action=browse&amp;-recid=665&gt; [retrieved on 20131127]</text><sources><source mxw-id="PNPL67387030" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>OCIO E M ET AL: "New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings", LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 9, no. 12, 1 December 2008 (2008-12-01), pages 1157 - 1165, XP025695499, ISSN: 1470-2045, [retrieved on 20081126], DOI: 10.1016/S1470-2045(08)70304-8</text><sources><source mxw-id="PNPL67387031" load-source="docdb" name="SEA" category="IA"/></sources></nplcit><nplcit><text>PALATH VARGHESE ET AL: "A Recombinant Human Antibody to EphA3 with Pro-Apoptotic and Enhanced ADCC Activity Shows Selective Cytotoxicity against Myeloid Leukemia Cells and CD123-Positive Leukemic Stem Cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 114, no. 22, 1 November 2009 (2009-11-01), pages 688, XP009137260, ISSN: 0006-4971</text><sources><source mxw-id="PNPL67387032" load-source="docdb" name="SEA" category="A"/></sources></nplcit><nplcit><text>See also references of WO 2011123819A2</text><sources><source mxw-id="PNPL67387033" load-source="docdb" name="SEA"/></sources></nplcit><nplcit><text>VEARING CHRISTOPHER ET AL: "Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-targeting reagents", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 15, 1 August 2005 (2005-08-01), pages 6745 - 6754, XP002493162, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-0758</text><sources><source mxw-id="PNPL67387034" load-source="docdb" name="SEA" category="A"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR919511141" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>KALOBIOS PHARMACEUTICALS INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919524547" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>KALOBIOS PHARMACEUTICALS, INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919546060" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>PALATH VARGHESE</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919522592" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>PALATH, VARGHESE</last-name></addressbook></inventor><inventor mxw-id="PPAR919537785" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>BEBBINGTON CHRISTOPHER R</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919544811" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>BEBBINGTON, CHRISTOPHER R.</last-name></addressbook></inventor></inventors></parties><international-convention-data><designated-states><ep-contracting-states><country mxw-id="DS549879654" load-source="docdb">AL</country><country mxw-id="DS549795288" load-source="docdb">AT</country><country mxw-id="DS549879655" load-source="docdb">BE</country><country mxw-id="DS549903473" load-source="docdb">BG</country><country mxw-id="DS549808786" load-source="docdb">CH</country><country mxw-id="DS549891576" load-source="docdb">CY</country><country mxw-id="DS549795297" load-source="docdb">CZ</country><country mxw-id="DS549879656" load-source="docdb">DE</country><country mxw-id="DS549891581" load-source="docdb">DK</country><country mxw-id="DS549891582" load-source="docdb">EE</country><country mxw-id="DS549928027" load-source="docdb">ES</country><country mxw-id="DS549903474" load-source="docdb">FI</country><country mxw-id="DS549903479" load-source="docdb">FR</country><country mxw-id="DS549879657" load-source="docdb">GB</country><country mxw-id="DS549891583" load-source="docdb">GR</country><country mxw-id="DS549879662" load-source="docdb">HR</country><country mxw-id="DS549795298" load-source="docdb">HU</country><country mxw-id="DS549808787" load-source="docdb">IE</country><country mxw-id="DS549891584" load-source="docdb">IS</country><country mxw-id="DS549903480" load-source="docdb">IT</country><country mxw-id="DS549891589" load-source="docdb">LI</country><country mxw-id="DS549895289" load-source="docdb">LT</country><country mxw-id="DS549795299" load-source="docdb">LU</country><country mxw-id="DS549895290" load-source="docdb">LV</country><country mxw-id="DS549895291" load-source="docdb">MC</country><country mxw-id="DS549798847" load-source="docdb">MK</country><country mxw-id="DS549798848" load-source="docdb">MT</country><country mxw-id="DS549795300" load-source="docdb">NL</country><country mxw-id="DS549928028" load-source="docdb">NO</country><country mxw-id="DS549808788" load-source="docdb">PL</country><country mxw-id="DS549895292" load-source="docdb">PT</country><country mxw-id="DS549795309" load-source="docdb">RO</country><country mxw-id="DS549895297" load-source="docdb">RS</country><country mxw-id="DS549808789" load-source="docdb">SE</country><country mxw-id="DS549895298" load-source="docdb">SI</country><country mxw-id="DS549928029" load-source="docdb">SK</country><country mxw-id="DS549808790" load-source="docdb">SM</country><country mxw-id="DS549798861" load-source="docdb">TR</country></ep-contracting-states></designated-states></international-convention-data></bibliographic-data><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
